Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
AssigneeBaxter Healthcare S.A.
InventorsJohannes Humer, Bernd Mayer, Thomas Muster, Andrea Waltenberger
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.
Claims2
An antibody characterized in that it is produced by the hybridoma cell line having DSMZ accession number DSM ACC2879.
A hybridoma cell line having DSMZ accession number DSM ACC2879.
Dependencies are inferred from the claim text.